Clinical Trial

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2025 (before its estimated August 19, 2025 completion). Its status may not reflect the trial's current state.
Summary
A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-16; most recent amendment 2025-03-04.
Status change: Recruiting → Active, Not Recruiting 2025-03-04
Status change: Not Yet Recruiting → Recruiting 2024-02-26
Trial Details
NCT Number NCT05913037
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Enrollment 167 participants
Start Date 2023-06-20
Primary Completion 2025-08-19 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-06